143

Neurology
Focuses on brain health.
Sub Categories on Neurology
Latest Articles
Detecting dementia in the blood

Detecting dementia in the blood

by Swiss Federal Laboratories for Materials Science and TechnologyEmpa researcher Peter Nirmalraj analyzes blood samples using atomic force microscopy (AFM). Credit: EmpaIf the suspicion of Alzhe

Detecting dementia in the blood

by Swiss Federal Laboratories for Materials Science and TechnologyEmpa researcher Peter Nirmalraj analyzes blood samples using atomic force microscopy (AFM). Credit: EmpaIf the suspicion of Alzhe
Hope for Alzheimer's blood test

Hope for Alzheimer's blood test

by Macquarie UniversityBoxplots comparing plasma Aβ1-42/Aβ1-40 ratio, p-tau181, GFAP, and NfL between CU Aβ−, CU Aβ+, MCI Aβ−, MCI Aβ+, and AD Aβ+ groups at timepoint 1. Plasma measures were comp

Hope for Alzheimer's blood test

by Macquarie UniversityBoxplots comparing plasma Aβ1-42/Aβ1-40 ratio, p-tau181, GFAP, and NfL between CU Aβ−, CU Aβ+, MCI Aβ−, MCI Aβ+, and AD Aβ+ groups at timepoint 1. Plasma measures were comp
FDA approves drug for rare form of ALS

FDA approves drug for rare form of ALS

by Cara MurezThe U.S. Food and Drug Administration on Tuesdayapproveda new drug for people who have a rare, inherited type of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig&

FDA approves drug for rare form of ALS

by Cara MurezThe U.S. Food and Drug Administration on Tuesdayapproveda new drug for people who have a rare, inherited type of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig&
Maria shriver and AARP take on Alzheimer's in women

Maria shriver and AARP take on Alzheimer's in women

by Serena Gordon, Healthday ReporterMaria Shriver(HealthDay)—An Alzheimer's diagnosis is devastating, no matter your sex. But the disease strikes far more women than men.Journalist and author Mari

Maria shriver and AARP take on Alzheimer's in women

by Serena Gordon, Healthday ReporterMaria Shriver(HealthDay)—An Alzheimer's diagnosis is devastating, no matter your sex. But the disease strikes far more women than men.Journalist and author Mari
Caregiver burden in dementia during the COVID-19 crisis

Caregiver burden in dementia during the COVID-19 crisis

by IOS PressCredit: CC0 Public DomainCaregivers of people with dementia and milder forms of neurocognitive disorder bear a heavy burden. They are constantly confronted with challenging symptoms a

Caregiver burden in dementia during the COVID-19 crisis

by IOS PressCredit: CC0 Public DomainCaregivers of people with dementia and milder forms of neurocognitive disorder bear a heavy burden. They are constantly confronted with challenging symptoms a
FDA panel urges rejection of experimental Alzheimer's drug

FDA panel urges rejection of experimental Alzheimer's drug

by Marilynn Marchione and Matthew PerroneIn this Dec. 12, 2019 photo provided by Biogen, a scientist works on Alzheimer's disease research in a laboratory at the drugmaker's headquarters in Ca

FDA panel urges rejection of experimental Alzheimer's drug

by Marilynn Marchione and Matthew PerroneIn this Dec. 12, 2019 photo provided by Biogen, a scientist works on Alzheimer's disease research in a laboratory at the drugmaker's headquarters in Ca
FDA approves first drug meant to ease Alzheimer's-linked agitation

FDA approves first drug meant to ease Alzheimer's-linked agitation

by Cara MurezA medication to treat agitation in Alzheimer's patients now has approval from the U.S. Food and Drug Administration.The FDA gave supplemental approval to Otsuka Pharmaceutical Company

FDA approves first drug meant to ease Alzheimer's-linked agitation

by Cara MurezA medication to treat agitation in Alzheimer's patients now has approval from the U.S. Food and Drug Administration.The FDA gave supplemental approval to Otsuka Pharmaceutical Company
FDA panel reviews 1st new Alzheimer's drug in 2 decades

FDA panel reviews 1st new Alzheimer's drug in 2 decades

by Marilynn Marchione and Matthew PerroneIn this Dec. 12, 2019 photo provided by Biogen, a scientist works on Alzheimer's disease research in a laboratory at the drugmaker's headquarters in Ca

FDA panel reviews 1st new Alzheimer's drug in 2 decades

by Marilynn Marchione and Matthew PerroneIn this Dec. 12, 2019 photo provided by Biogen, a scientist works on Alzheimer's disease research in a laboratory at the drugmaker's headquarters in Ca
Overlapping mechanisms in HIV cognitive disorders and Alzheimer's disease

Overlapping mechanisms in HIV cognitive disorders and Alzheimer's disease

by Society for NeuroscienceAβ oligomers are elevated in the brains of HIV(+) cases. Paraffin-embedded tissue sections from hippocampus of HIV(-) and HIV(+) individuals were prepared for immunoflu

Overlapping mechanisms in HIV cognitive disorders and Alzheimer's disease

by Society for NeuroscienceAβ oligomers are elevated in the brains of HIV(+) cases. Paraffin-embedded tissue sections from hippocampus of HIV(-) and HIV(+) individuals were prepared for immunoflu
GluN3A knockout mouse: Alternative model for Alzheimer's neurodegeneration

GluN3A knockout mouse: Alternative model for Alzheimer's neurodegeneration

by Emory UniversityGluN3A (in the diagram, NR3) is an inhibitory subunit within NMDA receptor assemblies, which function as glutamate-gated cation channels. GluN3A is a key regulator of neuronal

GluN3A knockout mouse: Alternative model for Alzheimer's neurodegeneration

by Emory UniversityGluN3A (in the diagram, NR3) is an inhibitory subunit within NMDA receptor assemblies, which function as glutamate-gated cation channels. GluN3A is a key regulator of neuronal
HBOT showed improvement in Alzheimer's disease

HBOT showed improvement in Alzheimer's disease

by Louisiana State UniversityCredit: Louisiana State UniversityDr. Paul Harch, Clinical Professor and Director of Hyperbaric Medicine at LSU Health New Orleans School of Medicine, and Dr. Edward

HBOT showed improvement in Alzheimer's disease

by Louisiana State UniversityCredit: Louisiana State UniversityDr. Paul Harch, Clinical Professor and Director of Hyperbaric Medicine at LSU Health New Orleans School of Medicine, and Dr. Edward
Clinical trial results for lecanemab are a significant step for Alzheimer's, but not a historic breakthrough

Clinical trial results for lecanemab are a significant step for Alzheimer's, but not a historic breakthrough

by University of New South WalesAmyloid plaques and neurofibrillary tangles occur in the brains of patients with Alzheimer's disease. Credit: Ian JosonPartner companies Eisai and Biogen recen

Clinical trial results for lecanemab are a significant step for Alzheimer's, but not a historic breakthrough

by University of New South WalesAmyloid plaques and neurofibrillary tangles occur in the brains of patients with Alzheimer's disease. Credit: Ian JosonPartner companies Eisai and Biogen recen